Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,988 | 3,053 | 6,958 | 9,127 | 13,644 |
| TOTAL | $4,673 | $3,819 | $7,011 | $9,329 | $13,997 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 258 | 342 | 0 | 0 | 0 |
| TOTAL | $258 | $342 | $N/A | $N/A | $N/A |
| Total Assets | $4,931 | $4,161 | $7,011 | $9,329 | $13,997 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,151 | 608 | 166 | 399 | 1,346 |
| Accrued Expenses | 1,132 | 2,292 | 4,175 | 3,045 | 3,016 |
| TOTAL | $2,283 | $2,968 | $4,341 | $3,512 | $4,362 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,283 | $2,968 | $4,341 | $3,512 | $4,362 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 37,741 | 37,570 | 35,639 | 35,052 | 34,671 |
| Common Shares | 38 | 36 | 36 | 35 | 35 |
| Retained earnings | -185,711 | -181,168 | -178,381 | -173,719 | -168,910 |
| Other shareholders' equity | 8,962 | 8,962 | 8,962 | 8,962 | 8,962 |
| TOTAL | $2,648 | $1,193 | $2,670 | $5,817 | $9,635 |
| Total Liabilities And Equity | $4,931 | $4,161 | $7,011 | $9,329 | $13,997 |